menu
    • menu

    Company profile for Natera

    NEW Drugs in Dev: 4
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Natera is looking for high performers who enjoy collaborating with others to solve complex problems and create meaningful solutions. When you join Natera, you’ll work hard and grow quickly. Working alongside the elite of the industry, you’ll be stretched and challenged, and take pride in being part of a company that is changing the landscape of genetic disease management.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    NateraUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    201 Industrial Rd San Carlos, CA 94070
    Telephone
    Telephone
    650.249.9090
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    --
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Natera To Present At 44Th J.P. Morgan Healthcare Conference
    Natera To Present At 44Th J.P. Morgan Healthcare Conference

    22 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251222257380/en/Natera-to-Participate-in-the-44th-Annual-J.P.-Morgan-Healthcare-Conference

    BUSINESSWIRE
    22 Dec 2025
    Share Share
    Natera Unveils Signatera in CALGB/SWOG CRC Study
    Natera Unveils Signatera in CALGB/SWOG CRC Study

    18 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251218169743/en/Natera-Announces-Publication-of-Signatera-Analysis-from-Randomized-Phase-III-CALGB-AllianceSWOG-80702-Study-in-Colorectal-Cancer

    BUSINESSWIRE
    18 Dec 2025
    Share Share
    I-SPY 2: Signatera Predicts Early Breast Cancer Recurrence
    I-SPY 2: Signatera Predicts Early Breast Cancer Recurrence

    16 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251216934410/en/I-SPY-2-Publication-in-Nature-Communications-Shows-Signatera-Can-Predict-Treatment-Response-and-Recurrence-Risk-in-Early-Stage-Breast-Cancer

    BUSINESSWIRE
    16 Dec 2025
    Share Share
    Natera Withdraws Appeal in NeoGenomics RaDaR Patent Litigation
    Natera Withdraws Appeal in NeoGenomics RaDaR Patent Litigation

    15 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251215508360/en/NeoGenomics-Announces-that-Natera-Has-Voluntarily-Withdrawn-its-Appeal-in-Ongoing-RaDaR-Patent-Litigation

    BUSINESSWIRE
    15 Dec 2025
    Share Share
    Natera and MEDSIR to Collaborate on the MiRaDoR Trial
    Natera and MEDSIR to Collaborate on the MiRaDoR Trial

    12 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251212609556/en/Natera-and-MEDSIR-to-Collaborate-on-the-MiRaDoR-Trial-in-Breast-Cancer

    BUSINESSWIRE
    12 Dec 2025
    Share Share
    PALLAS Study: Signatera MRD Testing Enhances Prognosis
    PALLAS Study: Signatera MRD Testing Enhances Prognosis

    10 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251210806608/en/Phase-III-PALLAS-Study-Shows-Signatera-MRD-Testing-Provides-Powerful-PostSurgical-Prognostic-Information-in-Patients-with-High-and-Intermediate-Risk-HRHER2-Breast-Cancer

    BUSINESSWIRE
    10 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search